These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33936101)

  • 1. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
    Yeku OO; Rao TD; Laster I; Kononenko A; Purdon TJ; Wang P; Cui Z; Liu H; Brentjens RJ; Spriggs D
    Front Immunol; 2021; 12():663379. PubMed ID: 33936101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
    Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
    Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.
    Jeon SH; You G; Park J; Chung Y; Park K; Kim H; Jeon J; Kim Y; Son WC; Jeong DS; Shin EC; Lee JY; Han DH; Jung J; Park SH
    Clin Cancer Res; 2024 Sep; 30(18):4155-4166. PubMed ID: 38743752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
    Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
    Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
    Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
    Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
    Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
    Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.
    Yuan Y; Li J; Chen J; Han L; Wang L; Yue Y; Liu J; Zhang B; Yuan Y; Wu M; Bian Y; Xie Y; Zhu J
    Biomed Pharmacother; 2024 May; 174():116565. PubMed ID: 38603888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
    Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
    Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
    Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B
    Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
    Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
    Front Immunol; 2021; 12():719116. PubMed ID: 34484225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
    Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.
    Chekmasova AA; Rao TD; Nikhamin Y; Park KJ; Levine DA; Spriggs DR; Brentjens RJ
    Clin Cancer Res; 2010 Jul; 16(14):3594-606. PubMed ID: 20628030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
    Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
    Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.